Health

Impact of NIH Funding Cuts on Drug Development – Healthcare Economist

• Health

Impact of NIH Funding Cuts on Drug Development – Healthcare Economist

Ak July 23, 2025

Last week, the Congress Budget Office (CBO) released a report, titled “Changes in funding for NIH and...

Read More Read more about Impact of NIH Funding Cuts on Drug Development – Healthcare Economist

What’s in the UK’s Life Sciences Sector Plan? – Healthcare Economist

• Health

What’s in the UK’s Life Sciences Sector Plan? – Healthcare Economist

Ak July 20, 2025

Yesterday, the UK government released it Life Sciences Sector Plan (LSSP). The British government introduced the provisions...

Read More Read more about What’s in the UK’s Life Sciences Sector Plan? – Healthcare Economist

Two approaches for measuring treatment value under uncertainty – Healthcare Economist

• Health

Two approaches for measuring treatment value under uncertainty – Healthcare Economist

Ak July 17, 2025

This is the title of my new paper Forum for Health Economics and Policy (FHEP) and subtitle...

Read More Read more about Two approaches for measuring treatment value under uncertainty – Healthcare Economist

Links

• Health

Links

Ak July 14, 2025

FDA: Fast-review voucher tied to reduce US prices Why FDA rejects drugs (in its own words) Kaiser...

Read More Read more about Links

Why CMS/AHIP’s prior authorization changes won’t hurt payers. – Healthcare Economist

• Health

Why CMS/AHIP’s prior authorization changes won’t hurt payers. – Healthcare Economist

Ak July 11, 2025

PhD published a new comment from FTI Consulting himself and Christie Picassini...

Read More Read more about Why CMS/AHIP’s prior authorization changes won’t hurt payers. – Healthcare Economist

Do orphan drugs deliver more survival gains per patient than non-orphan drugs? – Healthcare Economist

• Health

Do orphan drugs deliver more survival gains per patient than non-orphan drugs? – Healthcare Economist

Ak July 8, 2025

Traditional knowledge believes that orphan drugs treat rare (according to definition) and...

Read More Read more about Do orphan drugs deliver more survival gains per patient than non-orphan drugs? – Healthcare Economist

Friday Links

• Health

Friday Links

Ak July 5, 2025

Trends in non-care related to cost. OPTUM RX reduces the regeneration requirements. Changes in insulin out-of-pocket cost...

Read More Read more about Friday Links

Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease

• Health

Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease

Ak July 2, 2025

This is the title of my latest paper JMCP With co-author Jehong Kim, Shakshan Wang, Moise Marin,...

Read More Read more about Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease

Weekend Reading

• Health

Weekend Reading

Ak June 29, 2025

Naming schizophrenia: Why, how, and what next? Kovid -19 winner and losers. Labor market (not supply chain)...

Read More Read more about Weekend Reading

Impact of financial incentives on the value of the marginal drug – Healthcare Economist

• Health

Impact of financial incentives on the value of the marginal drug – Healthcare Economist

Ak June 26, 2025

From an interesting review letter in Economic approach journal By Craig Garthweight:...

Read More Read more about Impact of financial incentives on the value of the marginal drug – Healthcare Economist